Series completion is essential for protection3
The Advisory Committee on Immunization Practices recommends vaccines for CDC review and publication; all recommendations are eligible for first-dollar coverage.8
Clinical studies have shown faster protection with HEPLISAV-B1,9
DISCOVER DATAHEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
Please see full Prescribing Information.
References: 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 2. Engerix-B [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018. 3. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33. 4. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. JAMA Netw Open. 2020;3(11):e2027577. doi:10.1001/jamanetworkopen.2020.27577 5. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2022. Accessed April 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 6. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99(suppl 2):S389-S397. doi:10.2105/AJPH.2008.151332 7. Kim DK, Hunter P; for the Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2019. Ann Intern Med. 2019;170(3):182-192. doi:10.7326/M18-3600 8. Hughes R IV, Maxim R, Fix A. Vague vaccine recommendations may be leading to lack of provider clarity, confusion over coverage. Health Affairs Blog. May 7, 2019. Accessed April 14, 2022. https://www.healthaffairs.org/do/10.1377/forefront.20190506.172246 9. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD.
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.